Nitric Oxide Inhibition Simulates the Enhancement of α1Agonist-Induced Vasoconstriction in Diabetes

• Published in: The Journal of surgical research Vol. 70; no. 2; pp. 119 - 123
• Main Authors: Dresner, Lisa S., Wang, Stewart P., West, Michael W., Ponomarenko, Ihor N., Mueller, Cathy M., Wait, Richard B.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 01.07.1997; Elsevier
• Subjects: Biological and medical sciences; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Medical sciences; Endocrinopathy; Animal model; Pathophysiology; Rat; Diabetes mellitus; Rodentia; Experimental study; Biological activity; Vertebrata; Mesenteric artery; Mammalia; Induced vasoconstriction; Nitric oxide; Mechanism of action
• ISSN: 0022-4804; 1095-8673
• DOI: 10.1006/jsre.1997.5106

We have previously reported that endothelium-dependent, nitric oxide (NO)-mediated vasorelaxation is impaired in diabetic mesenteric arteries. We hypothesized that vasoconstrictor responses should therefore be enhanced. The purpose of this study was to determine whether diabetic mesenteric arteries exhibit increased vasoconstrictor responses, and to investigate if these changes are receptor and/or NO mediated. Thirty age-matched male Sprague–Dawley rats were divided into control (C) and diabetic (D, streptozotocin: 60 mg/kg) groups and studied after 4 weeks. Terminal branches of ileal mesenteric arteries (300 ± 9 μm) were isolated, pressurized, and superfused with modified Krebs solution. Changes in vessel internal diameter were measured and dose–response curves (DRC) for each vasoactive agent were determined. Each vessel was initially constricted with 40 mMof KCl to determine maximal vasoconstriction. Phenylephrine (Phe, 10−8–10−4M) and UK14304 (10−9–10−5M) were used to determine α1- and α2-receptor responses, respectively. Similar studies were performed in the presence ofNω-nitro-l-arginine methyl ester (l-NAME, 10−4M), a competitive inhibitor of NO synthase. Maximal response (Max), area under the curve (AUC), and vessel sensitivity (ED50) for each DRC were calculated. Comparisons among groups were made using analysis of variance and Student'sttest with Bonferroni correction. There were no differences in vasoconstrictor responses induced by KCl (C: 82 ± 2% vs D: 80 ± 1%). α1-vasoconstrictor responses to Phe were enhanced in diabetes with significantly higher Max (96 ± 2% vs 83 ± 3%), and AUC (1.92 ± 0.09 vs 1.56 ± 0.08), but no difference in ED50. The addition ofl-NAME enhanced only Phe-induced vasoconstrictor response significantly in control rats. Thus, differences in Phe-induced vasoconstrictor responses between C and D were abolished in the presence ofl-NAME. α2-vasodilator responses induced by UK14304 were similar between C and D and unaffected byl-NAME. α1-, but not α2-, vasoconstrictor responses are enhanced in streptozotocin-induced diabetic rats. These enhanced responses can be duplicated by treatment of control vessels withl-NAME.